Developer docs
API playgroundTry for free, no card

Search company profiles

Kyungdong Pharm

Full company profile

uuid000z2dp

Namestring
Kyungdong Pharm
Legal namestring
경동제약 주식회사
Websiteurl
kdpharma.co.kr
Company typeenum
Public
Founded yearint
1975
Descriptiontext

Kyungdong Pharm (경동제약, KRX: 011040) is a 50-year-old South Korean pharmaceutical manufacturer headquartered in Gwacheon, with production facilities in Hwaseong (Yanggam and Balan plants) and an on-site R&D Center operational since December 2015. Founded in 1975, the company's stated mission is to substitute domestically produced generics for previously imported essential medicines, and it now markets a portfolio of more than 183 prescription products, 34 OTC products, 15 health functional foods, and 45 active pharmaceutical ingredients (APIs).

The prescription portfolio is organized around chronic-disease therapy areas — cardiovascular (54 SKUs), diabetes (27 SKUs), anti-inflammatory/pain, antiviral, antibiotic, and antihistamine categories — and is differentiated by incrementally modified drugs (개량신약) such as Valdipin Plus (valsartan/amlodipine/chlorthalidone triple combination), Fenorovan (combination dyslipidemia), Dapazin SM SR (triple-combination T2D), and Nasopra (NSAID+PPI). The OTC line is anchored by the Gnal-N (그날엔) brand family in pain, cold, cough, and nasal categories, with the Gubamen sleep aid as a recent extension. Health functional foods span immune (Immune Vital Solution), stress (Ashwagandha, Theanine Relax Jelly, Magne & Kill Stress), eye health (Lutein), and gut health (Lactobacillus Probiotics) SKUs.

The business model is straightforward reimbursement-driven pharma unit sales: pricing on the prescription side is administered through Korean National Health Insurance 보험약가, with example hypertension SKUs priced at KRW 933–1,219 per tablet by dosage strength. Go-to-market is a hybrid enterprise field-sales motion into hospitals and clinics for Rx, plus retail distribution through Korean pharmacy networks for OTC and health functional foods, with API and finished-product export channels into Japan, Russia (since 1994), and at least ten other countries. Two recent strategic pivots — a January 2026 MOU with Hanil Electric Co. into beauty and wellness, and a pipeline of partnership agreements with Insereve (2022) and AuhlBio (2023) — point to deliberate diversification away from pure-play generics into adjacent health verticals and partnership-driven R&D.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, prescription medications, OTC medicines, active pharmaceutical ingredients, health functional foods
Industry3 codes
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals Manufacturing
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Prescription Drugs (전문의약품)
TypeOne Time License
Description

Sale of prescription medications including cardiovascular drugs, diabetes treatments, and other therapeutic categories

kdpharma.co.kr
2OTC Drugs (일반의약품)
TypeOne Time License
Description

Over-the-counter medications sold directly to consumers through pharmacies, including pain relievers like Gnal-N products

kdpharma.co.kr
3Health Functional Foods (건강기능식품)
TypeOne Time License
Description

Dietary supplements and functional health foods including probiotics, ashwagandha, lutein, and other products

kdpharma.co.kr
4Active Pharmaceutical Ingredients (원료의약품)
TypeOne Time License
Description

Manufacturing and export of APIs to international markets including Japan and other countries

kdpharma.co.kr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Operations, Marketing or Sales, Personnel, Infrastructure
Pricing details1 tier
1Prescription hypertension drug (발디핀플러스정)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Prices range from 933 won to 1,219 won per tablet depending on dosage strength

kdpharma.co.kr
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kyungdong Pharm manufactures and sells a broad portfolio of pharmaceutical products including generic prescription drugs, incrementally modified drugs (improved formulations and combination therapies), OTC consumer medicines (notably the Gnal-N brand family), health functional foods, and active pharmaceutical ingredients (APIs). The company operates its own manufacturing facilities in Hwaseong, produces over 90 prescription drugs and over 45 APIs, and distributes domestically through pharmacy networks and healthcare institutions while exporting APIs and finished products to Japan and more than 10 other countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Substituted billions of KRW worth of imported pharmaceuticals with domestically developed products
Product overview1 text field

Kyungdong Pharm is a mid-sized South Korean pharmaceutical company founded in 1975, operating as a unified portfolio of prescription drugs (183+ products), OTC consumer medicines (34+ products), health functional foods (15+ products), quasi-drugs, and active pharmaceutical ingredients (45+ products). The prescription portfolio is organized around core therapeutic areas — cardiovascular (54 products including Valdipin Plus, Telcardin, Rotodipine, Fenorovan), diabetes (28 products including Dapazin SM SR), and anti-inflammatory/pain treatments — combining generic drugs with incrementally modified drugs (improved combination formulations, new salts, novel dosage forms). The consumer OTC segment centers on the Gnal-N (그날엔) brand family for pain and cold symptom relief, with products like Gnal-N Q tablets, Gnal-N Cold Plus, and Gnal-N Cough Plus, plus the Gubamen (그밤엔) sleep aid. The health functional food lineup includes Immune Vital Solution, Ashwagandha, Magne & Kill Stress, Theanine Relax Jelly, and probiotic supplements. The company also manufactures and exports approximately 45 types of APIs. R&D activities cover generics, incrementally modified drugs, and biosimilar development including Dupixent biosimilars. Kyungdong Pharm has production facilities in Hwaseong (Yanggam and Balan plants) and an R&D center, with export operations to Japan and over 10 other countries.

Product and service1 record
1Prescription Drug Portfolio (전문의약품 Portfolio)
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-28
Description

Kyungdong Pharm signed an MOU with Hanil Electric Co. to jointly develop beauty and wellness products. This partnership represents the company's strategic pivot from generics-focused business to the beauty and healthcare market amid government generic drug price cuts.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Kyungdong Pharm signed MOU with AuhlBio for strategic partnership in January 2023.

3Insereve (인세리브로)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-06-01
Description

Kyungdong Pharm entered joint research agreement with Insereve for new drug development in June 2022.

kdpharma.co.kr
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kyungdong Pharm

Generic Pharmaceuticals Manufacturingkdpharma.co.kr

What Kyungdong Pharm does

Kyungdong Pharm (경동제약, KRX: 011040) is a 50-year-old South Korean pharmaceutical manufacturer headquartered in Gwacheon, with production facilities in Hwaseong (Yanggam and Balan plants) and an on-site R&D Center operational since December 2015. Founded in 1975, the company's stated mission is to substitute domestically produced generics for previously imported essential medicines, and it now markets a portfolio of more than 183 prescription products, 34 OTC products, 15 health functional foods, and 45 active pharmaceutical ingredients (APIs).

The prescription portfolio is organized around chronic-disease therapy areas — cardiovascular (54 SKUs), diabetes (27 SKUs), anti-inflammatory/pain, antiviral, antibiotic, and antihistamine categories — and is differentiated by incrementally modified drugs (개량신약) such as Valdipin Plus (valsartan/amlodipine/chlorthalidone triple combination), Fenorovan (combination dyslipidemia), Dapazin SM SR (triple-combination T2D), and Nasopra (NSAID+PPI). The OTC line is anchored by the Gnal-N (그날엔) brand family in pain, cold, cough, and nasal categories, with the Gubamen sleep aid as a recent extension. Health functional foods span immune (Immune Vital Solution), stress (Ashwagandha, Theanine Relax Jelly, Magne & Kill Stress), eye health (Lutein), and gut health (Lactobacillus Probiotics) SKUs.

The business model is straightforward reimbursement-driven pharma unit sales: pricing on the prescription side is administered through Korean National Health Insurance 보험약가, with example hypertension SKUs priced at KRW 933–1,219 per tablet by dosage strength. Go-to-market is a hybrid enterprise field-sales motion into hospitals and clinics for Rx, plus retail distribution through Korean pharmacy networks for OTC and health functional foods, with API and finished-product export channels into Japan, Russia (since 1994), and at least ten other countries. Two recent strategic pivots — a January 2026 MOU with Hanil Electric Co. into beauty and wellness, and a pipeline of partnership agreements with Insereve (2022) and AuhlBio (2023) — point to deliberate diversification away from pure-play generics into adjacent health verticals and partnership-driven R&D.

Kyungdong Pharm firmographics

Firmographics
Name
Kyungdong Pharm
Legal name
경동제약 주식회사
Website
https://kdpharma.co.kr
Company type
Public
Founded year
1975
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Kyungdong Pharm industry classification

Industry
Product category
Generic Pharmaceuticals Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Generic pharmaceuticals
  • Prescription medications
  • OTC medicines
  • Active pharmaceutical ingredients
  • Health functional foods

Where Kyungdong Pharm is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

Kyungdong Pharm business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Operations, Marketing or Sales, Personnel, Infrastructure

Revenue model

  1. Prescription Drugs (전문의약품): Sale of prescription medications including cardiovascular drugs, diabetes treatments, and other therapeutic categories
  2. OTC Drugs (일반의약품): Over-the-counter medications sold directly to consumers through pharmacies, including pain relievers like Gnal-N products
  3. Health Functional Foods (건강기능식품): Dietary supplements and functional health foods including probiotics, ashwagandha, lutein, and other products
  4. Active Pharmaceutical Ingredients (원료의약품): Manufacturing and export of APIs to international markets including Japan and other countries

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goPrescription hypertension drug (발디핀플러스정)

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Kyungdong Pharm product offering

Product offering

Core offering

Kyungdong Pharm manufactures and sells a broad portfolio of pharmaceutical products including generic prescription drugs, incrementally modified drugs (improved formulations and combination therapies), OTC consumer medicines (notably the Gnal-N brand family), health functional foods, and active pharmaceutical ingredients (APIs). The company operates its own manufacturing facilities in Hwaseong, produces over 90 prescription drugs and over 45 APIs, and distributes domestically through pharmacy networks and healthcare institutions while exporting APIs and finished products to Japan and more than 10 other countries.

Product overview

Kyungdong Pharm is a mid-sized South Korean pharmaceutical company founded in 1975, operating as a unified portfolio of prescription drugs (183+ products), OTC consumer medicines (34+ products), health functional foods (15+ products), quasi-drugs, and active pharmaceutical ingredients (45+ products). The prescription portfolio is organized around core therapeutic areas — cardiovascular (54 products including Valdipin Plus, Telcardin, Rotodipine, Fenorovan), diabetes (28 products including Dapazin SM SR), and anti-inflammatory/pain treatments — combining generic drugs with incrementally modified drugs (improved combination formulations, new salts, novel dosage forms). The consumer OTC segment centers on the Gnal-N (그날엔) brand family for pain and cold symptom relief, with products like Gnal-N Q tablets, Gnal-N Cold Plus, and Gnal-N Cough Plus, plus the Gubamen (그밤엔) sleep aid. The health functional food lineup includes Immune Vital Solution, Ashwagandha, Magne & Kill Stress, Theanine Relax Jelly, and probiotic supplements. The company also manufactures and exports approximately 45 types of APIs. R&D activities cover generics, incrementally modified drugs, and biosimilar development including Dupixent biosimilars. Kyungdong Pharm has production facilities in Hwaseong (Yanggam and Balan plants) and an R&D center, with export operations to Japan and over 10 other countries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Prescription Drug Portfolio (전문의약품 Portfolio)

Quantifiable outcome

  • Substituted billions of KRW worth of imported pharmaceuticals with domestically developed products

Companies that use Kyungdong Pharm

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Kyungdong Pharm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Kyungdong Pharm partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor.

  • Hanil Electric Co. (한일전기)minorStrategic or Co-development Partner · 28 January 2026Kyungdong Pharm signed an MOU with Hanil Electric Co. to jointly develop beauty and wellness products. This partnership represents the company's strategic pivot from generics-focused business to the beauty and healthcare market amid government generic drug price cuts.
  • AuhlBio (아울바이오)minorStrategic or Co-development Partner · 1 January 2023Kyungdong Pharm signed MOU with AuhlBio for strategic partnership in January 2023.
  • Insereve (인세리브로)minorStrategic or Co-development Partner · 1 June 2022Kyungdong Pharm entered joint research agreement with Insereve for new drug development in June 2022.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Kyungdong Pharm competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Kyungdong Pharm social profiles

Digital presence

Kyungdong Pharm compliance and trust

Trust signal

Compliance1 record

Kyungdong Pharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kyungdong Pharm leadership team

Management profile

Number of profiles

Profiles3 records

Kyungdong Pharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kyungdong Pharm M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kyungdong Pharm

What does Kyungdong Pharm do?

Kyungdong Pharm manufactures and sells a broad portfolio of pharmaceutical products including generic prescription drugs, incrementally modified drugs (improved formulations and combination therapies), OTC consumer medicines (notably the Gnal-N brand family), health functional foods, and active pharmaceutical ingredients (APIs). The company operates its own manufacturing facilities in Hwaseong, produces over 90 prescription drugs and over 45 APIs, and distributes domestically through pharmacy networks and healthcare institutions while exporting APIs and finished products to Japan and more than 10 other countries.

Is Kyungdong Pharm a public or private company?

Kyungdong Pharm is a public company. It is classified as public and is currently operating.

When was Kyungdong Pharm founded?

Kyungdong Pharm was founded in 1975. It employs 501 to 1,000 people.

Where is Kyungdong Pharm based?

Kyungdong Pharm is headquartered in Seoul, South Korea, in the Asia region.

How does Kyungdong Pharm make money?

Four revenue lines are on record. Prescription Drugs (전문의약품) is the primary driver. The others are OTC Drugs (일반의약품), health Functional Foods (건강기능식품) and active Pharmaceutical Ingredients (원료의약품).

Does Kyungdong Pharm have an API?

No public API is recorded for Kyungdong Pharm.

What industry is Kyungdong Pharm in?

Kyungdong Pharm's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAJAO, Compounding Ingredient & API Distributors (Pharma Supply). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingKyung Dong Pharmaceutical Honorary Chairman Raises Stake to 1.39% From 1.38%Honorary Chairman Ryu Deok-hee raised his Kyung Dong Pharmaceutical stake to 1.39% from 1.38%, holding 427,099 shares as of Oct. 30, 2026. He purchased 300 shares at KRW 4,980 on Oct. 26 and 3,100 at KRW 4,950 on Oct. 29.The Manila TimesKyungdong Pharmaceutical and Asimov Announce Completion of Cell Line Development Campaign for Biosimilar AntibodyKyungdong Pharmaceutical and Asimov announced the successful completion of a cell line development campaign for a biosimilar antibody candidate, with Asimov utilizing its proprietary CHO Edge System to produce a high-titer production cell line. This collaboration secures a foundation for Kyungdong’s process development and large-scale manufacturing of next-generation biosimilars. The achievement supports Kyungdong's strategic expansion into the biologics market and demonstrates the efficiency of Asimov's AI-driven synthetic biology platform.BioSpaceKyungdong Pharmaceutical and Asimov Announce Completion of Cell Line Development Campaign for Biosimilar AntibodyKyungdong Pharmaceutical and Asimov completed a cell line development campaign for a biosimilar antibody candidate, securing a high-performing production cell line. The collaboration used Asimov's CHO Edge System, achieving high titer for downstream process development and commercialization. Kyungdong plans to expand its biopharmaceutical business with this partnership.YahooKyungdong Pharmaceutical and Asimov Announce Completion of Cell Line Development Campaign for Biosimilar AntibodyKyungdong Pharmaceutical completed a cell line development campaign for a biosimilar antibody in collaboration with Asimov, using Asimov's AI-driven genetic design software. The development effort focused on creating a high-yield, high-quality production cell line to support future manufacturing and commercialization.GlobeNewswireKyungdong Pharmaceutical and Asimov Announce Completion of Cell Line Development Campaign for Biosimilar AntibodyKyungdong Pharmaceutical announced the completion of a cell line development campaign for a biosimilar antibody, in collaboration with Asimov. The project utilized Asimov's AI-driven platform, resulting in a high-titer cell line that supports process development and commercialization.ChosunbizKorean drugmakers pivot to beauty and aesthetics amid generic price cutsMidsize Korean pharmaceutical companies, including Ahngook Pharmaceutical and Kyungdong Pharm, are pivoting from a generics-centered business model to the beauty and healthcare market as the government prepares to cut new generic drug prices from 53.55% to 40% of original drug prices. Ahngook Pharmaceutical plans to amend its articles of incorporation to enter the aesthetics business and acquired Dmedi Korea in November last year, while Kyungdong Pharm signed an MOU with Hanil Electric Co. to jointly develop beauty and wellness products. Dongkook Pharmaceutical is cited as an early success case, having entered the cosmetics market in 2015 with its Centellian24 brand, which is expected to help the company surpass 1 trillion won in annual revenue this year.ChosunbizKorean firms race to develop Dupixent biosimilars ahead of 2031 patent expiryKorean pharmaceutical and biotech companies are developing biosimilars of Dupixent, which is expected to lose patent protection around 2031. Companies like KyungDong Pharm, Samsung Bioepis, and Daewoong Pharmaceutical are actively involved in research and development, aiming to capture a share of the expanding biosimilar market.Daum[fn Market Watch] Hyundai Technology Investment and Kyungdong Pharmaceutical invest 1.3 billion in Lettuce.Hyundai Technology Investment and Kyungdong Pharmaceutical provided a total of 1.3 billion won in seed investment to Letitu on the 10th. The capital will support Letitu's AI-driven platform, 'The Pond,' which offers personalized education courses for students seeking admission to American universities.TheguruHyundai Technology Investment and Kyungdong Pharmaceutical invest 1.3 billion won in the edutech company Lettitude.Hyundai Technology Investment and Kyungdong Pharmaceutical invested 1.3 billion won in seed funding for edutech company LETITU, which provides AI-driven personalized education programs for U.S. college admissions. The investment aims to support the expansion of LETITU's digital platform, which uses artificial intelligence to tailor learning paths for individual students. The company plans to launch its web-based services globally starting in March.